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Background: It is known that suboptimal adherence rates may affect endocrine treatments for breast cancer, but
little information has been reported whether any efforts to improve treatment adherence have been successful. We
designed a randomized, controlled study to investigate the effect of oral or written patient information program on
adherence and persistence when receiving an aromatase inhibitor (AI).
Methods: The study cohort included 181 female patients receiving an adjuvant AI treatment randomly assigned to
one of three groups. The first group received reminder letters and information booklets, the second group was
reminded and informed through telephone calls and the control group received neither. The primary endpoint was
the rate at which patients were classified as adhering to treatment after twelve months.
Results: Baseline results showed a well-balanced randomization with no significant differences between groups. After
12 months, 48% (CI 35–62) of the control group, 62.7% (CI 49–75) in the telephone group and 64.7% (CI 51–77) in the
letter group were adhering to therapy. A post hoc pooled analysis with a one-way hypothesis for both interventions
versus control indicated a significant difference between the groups favouring the intervention (p = 0.039).
Conclusion: The aim of this study was to investigate the efficacy of a simple and practical interventional program in
enhancing adherence to breast cancer treatment. Patients receiving additional/supplemental information appeared to
have an improved adherence rate even though the differences between groups were not statistically significant for the
primary endpoint.
Keywords: Adherence, Compliance, Aromatase inhibitors, Breast cancer, Endocrine treatmentBackground
In past decades, breast cancer survival rates have increased
substantially as a consequence of significant improvements
in early diagnosis and the introduction of more effec-
tive treatments e.g. adjuvant endocrine therapies. Third-
generation aromatase inhibitors (AIs) such as anastrozole
(1 mg/d), letrozole (2.5 mg/d), and exemestane (25 mg/d),
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reproduction in any medium, provided the orswitch and extended adjuvant treatments with regard to
disease-free survival (DFS) and distant metastasis (DM) in
postmenopausal women with hormone-sensitive early breast
cancer [1-3]. However, patients only attain maximum ben-
efits from their medications if they follow the instructions
and adhere to dosing schedules [4]. As with other chronic
diseases, patients with breast cancer often fail to take the
correct dosage at the prescribed frequency and for the
proper duration [5].
Awareness of poor patient adherence to treatment
programs has led to investigation of this issue by an in-
creasing number of clinical studies [6-9]. Due to the ser-
iousness of their disease, cancer patients are (generally)
considered highly motivated and compliant, but limitedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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vant treatment for breast cancer, and more specifically,
regarding the use of aromatase inhibitors. Recent studies
reported that up to 50% of patients stop taking their
medication during the course of 5 year adjuvant treat-
ment with tamoxifen, resulting in a significant increase
in mortality [10]. It was also reported that a substantial
proportion of patients on anastrozole fail to adhere to
the recommended treatment after the first year. In a dif-
ferent report, only 49% of patients with breast cancer
(BC) took adjuvant hormonal therapy for the full dur-
ation on the optimal schedule [11-16]. However, these
studies were health care data based analyses and do not
provide evidence about daily clinical routine treatment
at the patients level [13]. We recently reported the re-
sults of a study using a combination of self-reporting
and prescription refill counts in breast cancer patients
taking daily tamoxifen or anastrozole. After 12 months
of treatment, 80% of women on tamoxifen and 69% of
women on anastrozole were adhering to treatment [17].
With a growing number of patients surviving breast
cancer, the problem of adherence with therapy is becom-
ing increasingly important [13,18]. Increased adherence
and persistence are likely to improve patient outcomes,
and COMPAS (Compliance in Adjuvant treatment of
primary breast cancer Study) was designed to investigate
the effects of frequent reminders that informed and mo-
tivated patients with respect to breast cancer and its
treatment with an aromatase inhibitor. The aim of this
study was to investigate the efficacy of a simple and
practical intervention program on the ability of patients
to stay on treatment with an aromatase inhibitor for the
endocrine treatment of primary breast cancer.Methods
Objectives and definitions
In the absence of a reliable treatment-specific maker,
measuring patient adherence and persistence is a com-
plex challenge that (in a real life setting) can only be
achieved using surrogate endpoints. As it is impossible to
control for every medication intake/application, patients
need to be monitored by more or less crude subjective
measurements as a generally accepted “gold standard”
does not exist for measuring adherence and persistence.
Following the definition of ISPOR (International Society
for Pharmacoeconomics and Outcome Research), adher-
ence is “the degree or extent of conformity to the recom-
mendations about day-to-day treatment by the provider
with respect to the timing, dosage, and frequency” [19].
Another way to measure adherence is to estimate persist-
ence, which is defined as the duration of time from initi-
ation to discontinuation of therapy (8;19). A patient is
optimally adherent if no doses are missed, no extra dosesare taken and no doses are taken in the wrong quantity or
at the wrong time. A patient has optimal persistence if
they take a medication as long as it is prescribed [20].
Definition of adherence
Adherence was defined as the percentage of a prescribed
dose actually taken within a certain time frame. For this
study the adherence after 12 and 24 months after ther-
apy initiation was measured and we differentiated be-
tween self-reported adherence and prescription refill
counts. Prescription refill counts were used to calculate
the Medication Possession Ratio (MPR), which indicated
the recommended prescriptions to actual prescriptions
quotient. A patient was classified as adherent if self-
reported adherence and an MPR of 80% or more was
achieved. The limit of 80% was chosen based upon
current literature [13,15,21-23]
Definition of persistence
Persistence was defined as the duration (in months) of
therapy from initiation to discontinuation. Discontinu-
ation was defined as no medication (refills/in possession)
for at least 60 days or a discontinuation registered in the
patient file for whatever reason (e.g. due to side effects).
Measuring adherence and persistence
This study aimed to investigate the everyday-life setting
and only methods that did not stress or influence the pa-
tients were used.
To ensure these criteria, we combined two strategies:
1) Self-reported adherence using a specifically designed
and standardized questionnaire in combination with an
interview [17]. The questionnaire included 10 items
concerning aromatase inhibitor tolerance, side effects,
adherence and persistence. Furthermore, we added spe-
cifically designed questions that addressed side effects,
patient’s attitude towards breast cancer, their specific
treatment, their knowledge about breast cancer and
quality of life.
2) To add more objective criteria, we assessed pre-
scription refills and calculated the medication possession
ratio (MPR). Prescribed tablets were evaluated from hos-
pital charts and prescription refill details (i.e. number of
tablets prescribed, date of prescription, extra samples
donated, etc.) from all physicians involved in the treat-
ment of the patient (e.g. GP, Gynaecologist, Oncologist).
To ensure the completeness of the data, the patient, hos-
pital, GP, Gynaecologist and Oncologist were asked to
provide information for any physician known to be in-
volved in the prescribing process.
For the primary endpoint, these two measurements
were combined and patients classified as adherent if
both self-reporting and prescription refills indicated an
adherence above 80%. All interviews and the adherence
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interviewers and analysts not being informed about the
randomization results.Design
A single-centre, three-armed, randomized and partially-
blinded parallel group study was designed with the pri-
mary analysis at 12 and a secondary analysis planned for
24 months (not evaluated in this paper). Patients diag-
nosed with hormone receptor positive primary breast can-
cer that were recommended adjuvant treatment with an
aromatase inhibitor were recruited. Diagnosis and treat-
ment were initiated (independent of the study) according
to German breast cancer guidelines by the local the inter-
disciplinary breast cancer tumour board which is part of
the local comprehensive cancer centre. Study participation
was offered to all patients that met the inclusion criteria.Intervention
The intervention aimed to support patients in staying on
treatment by reminding, informing and motivating them.
Following the psychological principals of learning theory,
and using variable, intermittent re-enforcement, the in-
terventions were placed at doubling intervals during the
first year. This approach was designed to achieve max-
imum effect with reasonable practicability. Interventions
were planned for week 1, 2, 10, 20 and 33 in the first
year (after start of therapy) and months 15, 18 and 21 in
the second year (Figure 1).
Group 1 (Control group) – No intervention only stand-
ard information provided.Figure 1 Study scheme.Patients received baseline information in the hospital
and the 12 and 24 month interviews (visits).
Group 2 (Letter group) – Patients received a personal-
ized motivational reminder letter, informative content in
combination with a breast cancer information leaflet at
1, 2, 10, 20 and 33 weeks and at month 15, 18 and 21.
Patients were addressed personally, reminded of the
importance and impact of their disease, as well as the ef-
fects and possible side-effects of aromatase inhibitor
(AI) treatment. Each letter included contact information
and phone number for the study nurse available to an-
swer questions as well as information for when the doc-
tor should be contacted. The leaflet contained different
breast cancer related topics such as “sport and cancer”,
“nutrition and cancer”, etc.
Group 3 (Telephone group) – Patients were contacted
by a study nurse at week 1, 2, 10, 20 and 33 and month
15, 18 and 21 via telephone. Employing a semi-structured
interview technique, patients were reminded, informed
and motivated during the phone call. The call aimed to
provide individualized information, feedback to questions
and problems with medication or provide contact with the
treating oncologist if needed. Strategies were discussed
that ensured the regular intake of the tablets (“what will
you do to ensure you don’t forget to take a tablet?”,
“Where will you keep the tablets?”, etc.).
Visits
Patients were randomized to each group and baseline data
recorded during the hospital stay for primary treatment.
Specifically designed questionnaires were sent to each pa-
tient at 12 and 24 months in addition to a telephone
Telephone group 57 
Patients screened tumour board 2006 –2008
Breast Cancer receptor positive with Indication AI
n=321
Patients offered study participation after prescreening
n=202
Patients randomized    
n=181
Control group 57 Letter group 57
Patients excluded shortly after randomisation  -
no intervention performed, not analysed (per protocol) n=10
Figure 2 Consort diagram (12 month evaluation).
Ziller et al. BMC Cancer 2013, 13:407 Page 4 of 9
http://www.biomedcentral.com/1471-2407/13/407interview. Additionally other adherence related parame-
ters and clinical questions were captured.
Study population
Between April 2006 and December 2008, all patients re-
ceiving aromatase inhibitor therapy as an adjuvant treat-




 Primary breast cancer
 Aromatase inhibitor therapy following German
breast cancer guidelines [24].
 Informed consent
 Patient capable of using oral medication under their
own initiative following prescribing information.
Exclusion criteria
 Continuously hospitalized, residing in a nursing
home or receiving support via an ambulatory home
care service (or similar service).
 Suffering from any form of dementia or similar
disease interfering with memory.
 Other disease, mental or physical disorder that, in
the opinion of the study coordinator, would have
interfered with participation in the study.
 Known medical, drug or alcohol abuse.
Primary and secondary analytic end points and planned
analysis
The primary endpoint for the analysis was the propor-
tion of patients that could be classified “adherent” after
12 months according to pre-defined criteria. Adherence
was further analysed by self-reported adherence and
medication possession ratio. Secondary analysis evaluated
persistence and future analyses are planned to analyse
possible factors influencing adherence and persistence,
reasons for non-adherence and discontinuation, influence
of the interventions on other factors as knowledge of the
disease and quality of life.
Statistical analysis
With a group size of 60 per arm (including a drop-out
rate of ~10%), the study was designed to detect a mini-
mum interventional effect of 30% with α = 5%, 0.8 power
and two-way significance,
All analyses were performed using IBM-SPSS Version
17.0.
Descriptive analyses of the baseline characteristics, as
well as testing normal distribution, were performed using
the Kolmogorov-Smirnov-Test. Hypothesis testing wasperformed using Kruskal-Wallis, Chi-squared test or
T-test/U-test (Mann–Whitney) where applicable. Wilcoxon-
testing was applied for time-dependent tests and Kaplan-
Meier-Survival Analysis and Log Rank tests were used
to calculate persistence.
Ethics
The study was conducted in accordance to the guide-
lines and with approval of the local ethics committee of
the Philipps-University of Marburg.
Results
Patients (181) were recruited and randomized between
April 3rd, 2006 and December 18th, 2008 (Figure 2)
with a mean age at recruitment of 63.3 (SD 8.9). No sig-
nificant differences were found in baseline characteris-
tics with regards to age, BMI, tumour characteristics
(TNM-Classification, grading, receptor-status), primary
and adjuvant therapy, concomitant diseases, number of
concomitant medications, profession and others (Table 1).
Of these, 10 patients were excluded within four weeks
of randomisation as they no longer met inclusion cri-
teria (e.g. withdrew consent; 5 without providing a rea-
son, 2 due to other serious disease, 2 due to starting an
externally controlled treatment - home care service, 1
restarted menstruation just after randomisation and was
switched to tamoxifen). No further follow-up was per-
formed and they were counted as drop-outs.
The primary group endpoint revealed 48.0% (CI 35–62)
of patients in the control group, 64.7% (CI 51–77) in the
letter group and 62.7% (CI 49–75) in the phone group
were classified as adherent after 12 months (Figure 3).
The primary endpoint was comprised of self-reported ad-
herence and prescription refill counts. For self reported
Table 1 Baseline characteristics
Controls Phone group Letter group Total
n Mean/SD n Mean/SD n Mean/SD n Mean/SD
Age (years) 57 62,5/8,5 57 64,1/9,8 57 63,2/8,1 171 63,3/8,8
Number Children 57 1,8/1,2 57 1,9/1,1 57 1,91/1,4 171 1,8/1,3
Number concomitant disease 56 5,1/3,2 54 5,4/3,5 55 5,2/3,1 165 5,2/3,2
Number concomitant medications 57 2,5/3,1 54 2,6/2,8 54 2,4/2,4 169 2,5/2,8
Tumour data
Histology n % n % n % n %
Invasiv 56 98,2 58 100 59 100 173 99,4
Microinvasiv 1 1,8 0 0 0 0 1 0,6
Total 57 100 58 100 59 100 174 100
TNM n % n % n % n %
T1 33 57,9 37 62,7 37 63,8 107 61,5
T2 17 29,8 17 28,8 20 34,5 54 31
T3 6 10,5 3 5,1 1 1,7 10 5,7
T4 1 1,8 2 3,4 0 0 3 1,7
total 57 100 59 100 58 100 174 100
N0 27 47,4 32 54,2 26 44,8 85 48,9
N1 19 33,3 18 30,5 21 36,2 58 33,3
N2 8 14 5 8,5 6 10,3 19 10,9
N3 3 5,3 4 6,8 4 6,9 11 6,3
NX 0 0 0 0 1 1,7 1 0,6
Total 57 100 59 100 58 100 174 100
M0 56 98,2 57 96,6 57 98,3 170 97,7
M1 1 1,8 2 3,4 1 1,7 4 2,3
total 57 100 59 100 58 100 174 100
Treatment, surgery n % n % n % n %
Breast conserving therapy 42 73,7 37 62,7 42 72,4 121 69,5
Mastectomy 14 24,6 22 37,3 16 27,6 52 29,9
Total 57 100 59 100 58 100 174 100
Axillary node dissection (incl. SLN) 56 98,2 54 98,2 53 100 163 98,8
Radiotherapy n % n % n % n %
Negativ 2 3,5 6 10,5 4 7 12 7
Positiv 55 96,5 51 89,5 53 93 159 93
Total 57 100 57 100 57 100 171 100
Chemotherapy n % n % n % n %
Any 16 28,1 11 19,3 23 40,1 50 29,5
None 41 71,9 46 80,7 33 58,9 120 70,6
Total 57 100 57 100 56 100 170 100
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94.3% (CI 87–99) and 100% (CI 96–100) adherent patients
for controls, letter and phone group, respectively (Figure 3).
Prescription refills (80% cut-off) were achieved in 48% (CI
35–62), 64.7% (CI 51–76) and 62.7% (CI 48–74) in the
control group, letter group and phone group, respectively.The differences between the groups did not reach statis-
tical significance (Figure 3). A logistic regression analysis
did not show any significant influence on adherence for t-
stage, nodal status, chemo- and radiotherapy and interven-
tion group when entered as covariants in the model. To





























Figure 4 Persistence rate.
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lysis with a one-way hypothesis for both interventions
versus control was performed. This post hoc testing
indicated a significant difference between the groups
(p = 0.039).
Persistence was evaluated using Kaplan-Meyer Sur-
vival analysis and results are shown in Figure 4. The Log
Rank (Mantel-Haenszel) Test showed no significance be-
tween intervention groups (χ2 = 2.39; p = 0.305; df = 2).
Discontinuation was only based on medication refill, in
no case patient file information lead to further discon-
tinuation events. Mean medication possession ratio
and persistence is provided in Table 2. Mean Medication
Possession Ratio (MPR) and persistence were not
normally distributed by the Kolmogorov-Smirnov-Test.
Overall significance between groups was tested using the
Kruskal-Wallis-Test for MPR (χ2 = 3.83; p = 0.147) and
persistence (χ2 = 5.01; p = 0.082). A U-Test (Mann–
Whitney) for mean MPR did not reach statistical signifi-
cance when comparing control and letter groups (Z =
1.85; p = 0.064), no significance between control and
phone groups (Z = 1.48; p = 0.145) and between inter-
vention groups (Z = 0.44; p = 0.660).
When mean persistence was analysed, the difference
between control and letter groups (Z = 4.50; p = 0.034)
was significant, while no significant differences were
found between control and phone groups (Z = 1.55; p =
0.121) or between interventions (Z = 0.797; p = 0.426).
Self reported global medication tolerance at the 12 month
visit was bad or very bad in 23,6% of all patients (Table 3).
Grouping was performed according to primary endpoint.
When asked for reasons for interrupting treatment, 7.5% of
all patients admitted forgetting to take the medication while68% of those with treatment gaps did so due to side effects.
No significant differences were seen between groups.
Discussion
The well-established benefits of an adjuvant endocrine
treatment with aromatase inhibitors can only be
achieved if patients adhere to prescribed medications. A
lack in adherence may lead to reduced clinical outcomes,
unnecessary change of treatment, increased side effects
or even higher hospitalisation rates due to treatment
failure [20]. Despite the fact that women on adjuvant
Table 2 Mean MPR and persistence
Control Letter Phone Total
N = 51 N = 51 N = 53 N = 155
Mean SD Mean SD Mean SD Mean SD
MPR (%) 70.4 31.8 79.7 27.9 78.4 26.5 76.2 28.9
Persistence (weeks) 38.6 17.5 44.7 16.8 42.8 14.8 42.1 16.5
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expected to be highly adherent as they are facing a ser-
ious life threatening disease, the treatment is effective,
easy to use and generally well-tolerated, recent studies
underline a clinically relevant decrease in adherence to
tamoxifen and aromatase inhibitor therapy (including a
reduction in cancer outcome) as soon as 12 months
[13,14,25]. This indicated that patient statements and
the doctors’ perception with regards to adherence might
not always reflect reality.
Waterhouse et al. compared self-reported adherence,
classical pill count and the use of a micro electronic
monitoring device (MEMS) in tamoxifen patients and
found a significantly higher level of adherence was
recorded by patient self–reporting when compared to
MEMS (16.7% vs. 29% non-adherence at 3 months) [16].
Other studies evaluating adherence to tamoxifen, using
self-reported evaluation or database claim methods,
found adherence rates ranging from 65% to 85% for dif-
ferent periods of follow-up [13,26-29]. Barron et al. dem-
onstrated using prescription refill counts that by the end
of follow-up at 3.5 years, the cumulative non-persistence
rate had increased to 35.2% [30]. In an analysis by Par-
tridge et al. within the used claim databases, the mean
adherence to anastrozole significantly decreased from
78%-86% during the first year to 62%-79% during the
third year [15]. The authors themselves, using the same
methodology described for the COMPAS study comparing
adherence and persistence to tamoxifen and anastrozole
in the clinical practice, reported reduced adherence rates
for the adjuvant treatment of breast cancer [17]. This
served to illustrate the need for research to study and im-
plement strategies helping patients to stay on medications
and adhere to their treatment. However, improvingTable 3 Tolerance
Non-compliant Compliant Total
N % N % N %
Very bad 9 14.3 9 10.1 18 11.8
Bad 10 15.9 8 9.0 18 11.8
Indifferent 13 20.6 29 32.6 42 27.6
Good 21 33.3 27 30.3 48 31.6
Very good 10 15.9 16 18.0 26 17.1
Total 63 100.0 89 100.0 152 100.0adherence to aromatase inhibitor medication/treatment is
a complex and challenging issue that has not been suffi-
ciently studied [21].
We developed the COMPAS study in order to evaluate
the clinical efficacy of two simple/viable interventions
for improving adherence to adjuvant treatment with an
aromatase inhibitor in breast cancer patients. These in-
terventions provided a multifaceted approach to im-
proved knowledge of the disease, treatment advantages
and disadvantages in addition to explanations and solu-
tions for the patient. The semi-structured interview style
of the phone call from health professionals is designed
to enhance the effects by using elements of motivational
interviewing [31-33].
To measure adherence/persistence with a combination
of self-reported information and prescription refill counts
was a practical and fairly objective way to assess adherence
in a real-life setting. The evaluation of the baseline char-
acteristics showed a well-balanced randomization and
a representative sample structure of the investigated
patients while the baseline demographic characteristics
of our real-life sample were comparable to study popu-
lations in pivotal aromatase inhibitor trials with regard
to age, tumour characteristics and primary therapy
[1-3]. They also show that the German guidelines for
treatment initiation had been followed as suggested
[24].
Evaluation of the primary endpoint revealed marked
differences between the groups, even though the differ-
ences did not reach statistical significance. The authors
are convinced there was a clinically significant effect for
the interventions as demonstrated by the numerical in-
crease for both interventions. Additionally, after pooling
the intervention groups, a significant difference could be
found in mean persistence. This cannot be taken as a
final proof of concept, but should encourage the devel-
opment of further interventions and studies containing a
greater number of patients.
Kaplan-Meyer analysis for persistence showed that after
one year a marked number of patients had discontinued
treatment. There was a slight but statistically insignificant
improvement due to the interventions. The reasons for
non-adherence and non-persistence were diverse and the
authors believe that only interventions that address mul-
tiple issues in the patients everyday life would lead to sig-
nificant improvements.
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[13]. The COMPAS study showed a positive side-effect
profile, with 49.7% of patients reporting good or very good
tolerance to their aromatase inhibitor
Non-adherent patients had slightly lower tolerance, but
the difference was not statistically significant. There were
no differences in the rate of patients that stopped treat-
ment due to tolerance issues. Furthermore no other
baseline parameters showed significant associations to ad-
herence outcome. From the patients view, remembering
to take the medication did not seem to be an issue as only
7.5% reported “forgetting” to take the tablets. Interven-
tions that could enhance adherence would need to specif-
ically address individual problems that occurred over time
and due to individual habits, side effect(s), coping strat-
egies, health belief and others.
Conclusions
COMPAS was designed to use personalized, multifaceted
approaches to support numerous patients with a viable
cost effective approach. Even so, the effects on adherence
and persistence were not as significant as expected.
Assisting patients with taking their medications should
improve therapeutic outcome and efficiency, which would
be of upmost importance to the individual, therefore fur-
ther scientific effort is needed to reach those aims.
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